Timing of interferon therapy and sources of infection in patients with acute hepatitis C.

Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Abstract Text:

Kei Ogata,Tatsuya Ide,Ryukichi Kumashiro,Hiromitsu Kumada,Hiroshi Yotsuyanagi,Kiwamu Okita,Yoshihiro Akahane,Shuichi Kaneko,Hirohito Tsubouchi,Eiji Tanaka,Hisataka Moriwaki,Shuhei Nishiguchi,Shinichi Kakumu,Masashi Mizokami,Shiro Iino,Michio Sata,

BACKGROUND/AIMS: Controversy over the selection of patients and optimum therapeutic method for acute hepatitis C has continued. The aims of this study were to investigate the source of infection, and to evaluate the timing of interferon (IFN) therapy in patients with acute hepatitis C in Japan. METHODS: The records of 102 patients from 12 facilities in Japan who developed acute hepatitis C after 1990 were investigated. In the patients treated with IFN, we performed multivariate analysis to investigate factors related to sustained virological response (SVR). RESULTS: Medical procedure was the most common source of infection, accounting for 32.4% in the 102 patients (33/102). Of 81 patients treated with IFN, 71 patients were followed after IFN therapy, and 57/71 (80.3%) had SVR. The SVR rate was significantly higher in patients treated with IFN within 24 weeks from onset of symptoms than the SVR rate in those treated after 25 weeks (P=0.0016). Multivariate analysis revealed that only the duration between onset of symptoms and initiation of IFN therapy (within 24 weeks) was related to SVR. CONCLUSIONS: Our multicenter cooperative survey revealed that medical procedure was the most frequent source of infection in acute hepatitis C. As concerns the therapy, interferon treatment should be initiated within 24 weeks after onset of symptoms.

Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Publishing Authors By Initials

K Ogata,T Ide,R Kumashiro,H Kumada,H Yotsuyanagi,K Okita,Y Akahane,S Kaneko,H Tsubouchi,E Tanaka,H Moriwaki,S Nishiguchi,S Kakumu,M Mizokami,S Iino,M Sata,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hepatology research : the official journal of the

VOLUME: 34

Page Numbers: 35-40

Journal Abbreviation:

ISSN: 1386-6346

DAY: 15

MONTH: 12

YEAR: 2005

Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9711801

Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Timing of interferon therapy and sources of infection in patients with acute hepatitis C.

AFFILIATION: Second Department of Internal Medicine, Kurume University, Fukuoka, Japan.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hepatol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Timing of interferon therapy and sources of infection in patients with acute hepatitis C Related Publications

• A human T-cell lymphotropic virus type-1 (HTLV-1) carrier complicated with various autoimmune diseases including primary biliary cirrhosis.
• Accumulation of mono-glycosylated form-rich, plaque-forming PrPSc in the second atypical bovine spongiform encephalopathy case in Japan.
• Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance.
• Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins.
• Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases.
• Chlamydia trachomatis proctitis.
• Confocal laser microscopy of chondrocytes that received gene transfer using in vitro electroporation.
• Considerations for general anesthesia combined with epidural anesthesia in a patient with stiff-person syndrome.
• Epidemiological survey of oral lichen planus among HCV-infected inhabitants in a town in Hiroshima Prefecture in Japan from 2000 to 2003.
• Granulocytapheresis (GCAP) for severe alcoholic hepatitis-A preliminary report.
• Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
• HBV and HCV infection in Japanese dental care workers.
• Insulin resistance and lichen planus in patients with HCV-infectious liver diseases.
• Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
• Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis.
• Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
• Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.
• Open sesame! CXCR4 blockade recruits neutrophils into the plaque.
• Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells.
• Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes.
• Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
• Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients.
• Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection.
• Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-elicited Hepatic Insulin Resistance via Peroxisome Proliferator-activated Receptor-gamma Activation.
• The Effects of Ethanol on beta2-Integrin and l-Selectin on the Surface of Leukocytes in Human Whole Blood.
• The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function.
• Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
• Timing of interferon therapy and sources of infection in patients with acute hepatitis C.
• [A periappendiceal abscess during combination interferon and ribavirin treatment for chronic hepatitis C]
• [Incidence of insertion difficulty using Proseal LMA and the efficacy of recommended insertion maneuvers]